Luvme Announces 2026 New Year New Look Offers Starting at $74.9
NEW YORK–(BUSINESS WIRE)–#luvme—Luvme Hair, a trusted brand in colored human hair wigs and glueless lace wig, is kicking off the year with its... Read more.
FairJourney Bio to present at J.P. Morgan 2026 Healthcare Conference
PORTO, Portugal–(BUSINESS WIRE)–FairJourney Bio (FJBio), a global leader in antibody discovery and development, announced today that its Chief Executive... Read more.
Active Membranes Appoints Eric Hoek as Executive Chairman to Accelerate Strategy, Fundraising, and Commercialization
LOS ANGELES–(BUSINESS WIRE)–#Desalination—Active Membranes, Inc., a developer of next-generation membrane technologies that significantly reduce... Read more.
AF Blakemore Selects Logile to Standardise Labour Planning Across Its Retail Estate
Leading UK retailer partners with Logile’s Labour Planning suite to optimise workforce performance and enhance the customer experience. DALLAS–(BUSINESS... Read more.
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program
HANOI, Vietnam–(BUSINESS WIRE)–$FPT #FPT–Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new... Read more.
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy
Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer to further... Read more.
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors
SCHAUMBURG, Ill.–(BUSINESS WIRE)–Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen... Read more.
Allotex Advances from European Commercialization to U.S. Clinical Phase
BOSTON–(BUSINESS WIRE)–#eye–Allotex Inc., a commercial-stage ophthalmic company with active European market adoption, today announced that the... Read more.
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept... Read more.
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially... Read more.